Initial Public Offer of 8,729,023* equity shares of face value of Rs.5 each ("equity shares") of Windlas Biotech Limited ("company" Rs.455 per equity share) aggregating to Rs.401.54 Crores (the "offer") comprising a fresh issue of 3,586,956* equity shares aggregating to Rs.165 Crores (the "fresh issue") and an offer for sale of 5,142,067* equity shares, comprising of 1,136,000* equity shares aggregating to Rs.52.26* Crores by Vimla Windlass (the "individual selling shareholder") and 4,006,067* equity shares aggregating to Rs.184.28* Crores by Tano India Private Equity Fund II (the "investor selling shareholder", and collectively with the individual selling shareholder, the "selling shareholders", and such equity shares, the "offered shares") aggregating to Rs.236.54 Crores (the "offer for sale). The offer constitutes 40.05% of the post-offer paid-up equity share capital of the Company.
The face value of equity shares is Rs.5 each. The offer price is Rs.460 per equity share and is 92 times the face value of the equity shares.
*subject to finalisation of the basis of allotment.
Issue
Money Payable On
Opens On
Closes On
Application
Allotment
04-Aug-2021
06-Aug-2021
₹ 460.00
₹ 0.00
Minimum Application for shares in Nos : 30.0
Further Multiples of : 30.0
(₹)Cr.
Lead Managers to the Issue
Project Cost
165.00
DAM Capital Advisors Ltd
Project Financed through Current Offer
401.54
Post Issue Equity Share Capital
10.90
Issue Price
₹460.00
Projects
Purchase of Equipment required for (i) Capacity Expansion of the existing facility at the Dehradun Plant-IV and (II) Addition of Injectables Dosage Capability at the existing facility at Dehradun Plant - II
Funding Incremental Working Capital Requirements of the Company